Ceramide has emerged as an important signal transduction molecule that has been shown to play a role in such fundamental biological processes as proliferation, differentiation, receptor function, oncogenesis, and immune and inflammatory responses (1-3). Ceramide is generated by the hydrolysis of sphingomyelin (SM) via the activation of both neutral and acidic sphingomyelinase (SMase) (4). SM hydrolysis is stimulated by specific cytokines such as TNF-α (5-7), IFN-γ (8), and IL-1β (9, 10). Noncytokine inducers of SM hydrolysis include 1α,25-dihydroxyvitamin D3 (11) and brefeldin A (12).

We and others have shown that IL-1β stimulates SM hydrolysis and the accumulation of ceramide in fibroblasts and EL4 lymphoma cells (9, 10). We also showed that ceramide modulated the effects of IL-1β on PGE2 production in human fibroblasts via its ability to enhance the expression of the cyclooxygenase-1 gene (9). The ability of ceramide to modulate the effects of IL-1β on PGE2 production led us to examine the effects of ceramide on IL-1β-mediated IL-6 production. IL-6 is a multifunctional cytokine produced by monocytes and macrophages, endothelial cells, vascular smooth muscle cells, and fibroblasts (13-16). IL-6 is known to activate T cells, promote B cell growth and Ig synthesis, stimulate synthesis of acute phase proteins by hepatocytes, act as an endogenous pyrogen, induce megakaryocyte maturation, stimulate proliferation of keratinocytes, and act as a growth factor for human myeloma and murine plasctocytoma (15). IL-6 has been implicated in inflammation (13, 14, 17), viral infection (18), autoimmune (15), development (19), and malignant cell growth (15).

In an effort to establish the role of ceramide in IL-1β-induced IL-6 production, we treated cells with stereoisomers of C2-ceramide or exogenous SMase and measured IL-6 protein and messenger RNA (mRNA) levels. Here we show that the treatment of human fibroblasts with ceramide or with exogenous SMase induces IL-6 expression in a time- and dose-dependent manner. D-C2-ceramide, but not L-C2-ceramide, induced significant production of IL-6 protein and mRNA at submicromolar concentrations, indicating a high degree of specificity for ceramide and the induction of IL-6 gene expression. Our findings suggest that ceramide may play a role in the regulation of IL-6 expression.
Materials and Methods

Materials. IL-6, IL-1β, IL-1α, and TNF-α immunoassay kits were obtained from R&D Systems (Quantikine; Minneapolis, MN). Bacterial SMase (Staphylococcus aureus) was obtained from Sigma Chemical Co. (St. Louis, MO) and not purified further; using an in vitro assay system to test the specificity of hydrolysis, phosphatidylcholine was hydrolyzed <5% compared with SM (100%). Ceramide stereoisomers were prepared and analyzed by nuclear magnetic resonance as previously described (20).

Cell Culture. Human foreskin fibroblasts were maintained in culture as previously described (9). Confluent fibroblast cultures were incubated with fatty acid-free BSA for 1 h as previously described along with appropriate vehicle controls. Ceramide stereoisomers were incubated with fatty acid-free BSA for 1 h as previously described (9) before their addition. The effect of ceramide on cell viability was assessed using trypan blue exclusion and DNA fragmentation; at all concentrations tested, ceramide had no apparent adverse affects.

Immunoassay of IL-6 and IL-1. IL-6, IL-1α, IL-1β, and TNF-α levels in cell supernatants were measured by ELISA (R&D Systems) according to the manufacturer's directions.

RNA Isolation and Northern Analysis of IL-6. Total fibroblast cellular RNA was isolated from treated cells using the RNAzol method (Tel-Test, Inc., Friendswood, TX). RNA was fractionated on 1.2% agarose gels containing formaldehyde and blotted onto nitrocellulose membranes using capillary transfer (21). Blots were hybridized with either a 32P-labeled IL-6 or GAPDH probe. Sequences used as probes were generated by RT-PCR using the following primers derived from human DNA sequences: IL-6 sense 5'-CCA CCC ATG GCA AAT TCC AT(3 GCA-3'/antisense 5'-GGA CTG CAG GAA CTC CTT-3'; IL-6 antisense 5'-TCT CTG CAG GAA CTC CTT-3'/antisense 5'-AAA GC-3' (22); GAPDH sense 5'-CCA CCC ATG GCA AAT TCC ATG GCA-3'/antisense 5'-TCT AGA CGG CAG GTC AGG GCC ACC-3' (23). The PCR fragments were cloned into pCR II (Invitrogen, San Diego, CA). EcoRI-released inserts were subsequently used as substrates for random primer labeling. Hybridizations were performed for 16-20 h at 42°C in sodium chloride sodium phosphate EDTA buffer containing 50% formamide. Hybridized membranes were autoradiographed on X-OMAT film (Eastman Kodak Co., Rochester, NY) at -80°C.

Results

Ceramide Induces IL-6 Expression. In human foreskin fibroblasts, IL-1β has been shown to induce SM hydrolysis and the accumulation of ceramide within 2 h (9), and IL-1β is also known to be a potent inducer of IL-6 expression in these cells. Therefore, in an effort to establish whether ceramide is involved in the signal transduction pathway by which IL-1β induces IL-6 production, cells were treated with stereoisomers of C2-ceramide (1 μM final concentration), bacterial SMase (1 μU/ml), or IL-1β. After an overnight incubation, culture media were collected and IL-6 protein levels were measured by ELISA. As shown in Fig. 1, both D-erythro- and L-threo-C2-ceramide induced IL-6 production to a similar extent as did IL-1β, while both L-erythro- and D-threo-C2-ceramide were ineffective inducers of IL-6 production. This is not likely to be an artifact of unequal ceramide uptake, as others have shown that these stereoisomers are taken up by cells with equal efficiency (20). Consistent with the hypothesis that SM hydrolysis may be involved in the IL-1β signaling pathway leading to IL-6 synthesis, treatment of cells with bacterial SMase also induced IL-6 production (Fig. 1). When cells were treated with actinomycin D to inhibit transcription, IL-6 production in response to IL-1β, C2-ceramide, and bacterial SMase was reduced >95%, indicating regulation of IL-6 induction at the transcriptional level (data not shown). Ceramide did not induce IL-1α, IL-1β, or TNF-α production in these cells, which could have resulted in an autocrine induction of IL-6 synthesis. Also, cells pretreated with IL-1 receptor antagonist protein (5 ng/well) inhibited IL-1-induced IL-6 production but had no effect on D-C2-ceramide-induced IL-6 production (data not shown), suggesting that ceramide is able to induce IL-6 production in the absence of IL-1 receptor stimulation. Figure 1. The structures of the stereoisomers of C2-ceramide (A), and the effect of IL-1β, C2-ceramide isomers, and bacterial SMase on IL-6 induction (B). Confluent dermal fibroblasts were treated with 1 μM (final) D- or L-threo-C2-ceramide, D- or L-erythro-C2-ceramide, 50 pg/ml IL-1β, bacterial SMase (1 μU/ml), or vehicle control in serum-free medium. After 24 h, culture media were collected and IL-6 protein levels were measured by ELISA. All data points depicted were derived from duplicate IL-6 assays from two identically treated wells ± SD. Five independent experiments gave similar quantitative data.
production. \(d\)-erythro-C2-ceramide effectively induced IL-6 production, but only at somewhat higher concentrations than the \(d\)-threo isomer. In contrast, neither of the \(l\) forms of ceramide were effective inducers of IL-6 production (Fig. 2). It is noteworthy that the submicromolar concentration of \(d\)-C2-ceramide needed to induce IL-6 gene expression is among the lowest reported for such compounds to elicit a specific biological response.

**Time Course for IL-1\(\beta\), Ceramide, and Bacterial SMase-induced IL-6 Expression.** Cells were treated with either IL-1\(\beta\), \(d\)-threo-C2-ceramide (selected for further study because it was the most potent ceramide isomer tested), or bacterial SMase for the times indicated, and IL-6 production was measured (Fig. 3). IL-1\(\beta\) rapidly induced IL-6 production, with \(\sim 80\%\) of the maximal stimulation occurring by 2 h of incubation and 100% stimulation by 6 h of incubation. Although both \(d\)-threo-C2-ceramide and SMase induced measurable IL-6 production by 2 h of incubation, both treatments were significantly less effective than IL-1\(\beta\), suggesting the activation of multiple pathways by IL-1\(\beta\) leading to IL-6 production. As the time of incubation increased, both \(d\)-threo-C2-ceramide- and SMase-induced IL-6 production continued to increase; by the end of a 24-h treatment, cells treated with either IL-1\(\beta\), \(d\)-threo-C2-ceramide, or SMase produced essentially equivalent amounts of IL-6 (Fig. 3).

**Steady State Levels of IL-6 mRNA Induced by \(d\)-threo-C2 Ceramide** Total RNA from cells treated with increasing concentrations of \(d\)-threo-C2-ceramide was size fractionated, blotted, and hybridized with an IL-6 cDNA probe. The same Northern blot was also hybridized with a GAPDH cDNA probe to monitor changes in a constitutively expressed mRNA after treatment with C2-ceramide. Fig. 4 shows the data from a representative dose–response experiment in which cells were treated with \(d\)-threo-C2-ceramide at the concentrations indicated for 24 h. There was a clear, dose-dependent increase in IL-6 mRNA in response to ceramide, and significant IL-6 induction was observed at the lowest concentration tested in these experiments, \(5 \times 10^{-9} \text{ M}\). The specificity of IL-6 mRNA induction can be readily appreciated from the lack of significant changes in the steady state levels of GAPDH mRNA (Fig. 4).

To establish the time course of IL-6 mRNA induction in response to ceramide, cells were treated with \(d\)-threo-C2-ceramide for 0, 1, 3, 6, and 24 h, and total RNA was analyzed by Northern hybridization as above. Ceramide rapidly induced IL-6 mRNA, which was detectable by 1 h and dramatically increased by 3 h (Fig. 5). We consistently observed a slight decrease in IL-6 mRNA levels after 6 h of incubation; however, no corresponding decrease in IL-6 protein levels was seen at 6 h. IL-6 mRNA levels continued to increase over the remaining course of the incubation with ceramide.
with the addition of nanomolar concentrations of blasts was somewhat slower in ceramide-treated cells than mide could be due to the possibility that the activation of IL-13-treated cells, equivalent IL-6 levels accumulated by ceramide required concentrations well below the levels known Cz-ceramide. Maximal induction of IL-6 in response to cer-

Although the kinetics of induction of IL-6 by human fibro-

glycerol/protein kinase C pathway (26). Because of the acti-

pathway involved in the IL-1/3-mediated induction of Ib6. This is likely, because IL-13-induced IL-6 production in cul-

the SM pathway accounts for only a portion of the signaling action. Because the cAMP/protein kinase A pathway (27) and the diacyl-

protein kinase C (26) and cAMP-dependent protein kinase

Discussion

IL-6 is a multifunctional cytokine produced by many different cell types, including fibroblasts. The expression of IL-6 is regulated by a variety of agonists, including IL-1, TNF-α, platelet-derived growth factor, interferons, and glucocorticoids (24, 25). Studies of IL-6 induction in response to TNF-α and IL-1β in human fibroblasts have revealed that both the protein kinase C (26) and cAMP-dependent protein kinase A pathways (27) are involved. However, it is also recognized that these signaling pathways may not completely account for IL-6 induction by IL-1β and TNF-α (28). Because these cytokines also stimulate SM hydrolysis, resulting in increased intracellular ceramide (8, 9), we examined the possibility that ceramide may be involved in the signaling pathway leading to the induction of IL-6 production.

IL-6 gene expression in human fibroblasts was inducible with the addition of nanomolar concentrations of D-threo-

C2-ceramide. Maximal induction of IL-6 in response to cer-

amide required concentrations well below the levels known to result in toxicity or apoptosis in cultured cells (29, 30). Although the kinetics of induction of IL-6 by human fibro-

blasts was somewhat slower in ceramide-treated cells than in IL-1β-treated cells, equivalent IL-6 levels accumulated by 24 h. The difference in time courses between IL-1β and cera-

mide could be due to the possibility that the activation of the SM pathway accounts for only a portion of the signaling pathway involved in the IL-1β-mediated induction of IL-6. This is likely, because IL-1β-induced IL-6 production in cultured human fibroblasts has been shown to involve both the cAMP/protein kinase A pathway (27) and the diacyl-

glycerol/protein kinase C pathway (26). Because of the activ-

ation of multiple stimulatory pathways in addition to the SM pathway, the more rapid induction of IL-6 production in response to IL-1β, compared with the addition of exogenous ceramide by itself, is not an unexpected result. IL-1 causes an increase in cAMP levels more quickly than it causes an increase in ceramide levels. Another possible reason for the time course difference between IL-1β and C2-ceramide-mediated induction of IL-6 could be a difference in "effective" concentration of ceramide at a specific site of action. Because the IL-1β receptor is most likely linked to the activation of a "specific" SMase, the receptor-coupled action of IL-1β could result in a higher concentration of ceramide at a specific site of action when compared with intracellular levels of cer-

amide entering the cell by nonspecific diffusion through the plasma membrane. Although SMase-mediated IL-6 induction is somewhat slower than that of C2-ceramide, the level of IL-6 after 24 h is similar to that induced by IL-1β and C2-

ceramide. This might be due to the rate at which ceramide is produced in response to exogenous SMase treatment. It is also possible that the time course difference between SMase and C2-ceramide relates to the difference in length of amidelinked acyl chains between C2-ceramide and the natural cer-

amide (mostly C16-ceramide), or it may be due to the fact that, unlike natural C16-ceramide, C2-ceramide is not metabolized and therefore provides a more stable signal.

Our results indicate that the D isomers of ceramide are far better inducers of IL-6 than are the corresponding L isomers. In contrast, the L isomers of ceramide have been shown to be more effective than the D isomers for inhibiting the proliferation of HL-60 cells (20). These unique specificities for ceramide stereoisomers in different cell types remain an enigmatic question and suggest potential differences in the cellular targets for ceramide action. With respect to targets of ceramide action, there have been at least two ceramide-activated enzymes described: a proline-directed serine/threonine protein kinase (5) and a ceramide-activated protein phosphatase (CAPP) (31). At the present time, it is not known whether either of those two enzymes is involved in the induction of IL-6 or whether the activation of another as yet unidentified signal transduction pathway is involved.

Our finding that the D isomers of ceramide are more effec-
tive than the L isomers in the induction of IL-6 expression implicates the stereochemistry at carbon 3 as critical for their action. The number 3 carbon was also concluded to be important using structural analogues of ceramide in regulating cellular proliferation (29). The specificity of ceramide for IL-6 gene induction would appear to be different from that of the activation of CAPP, in which all four ceramide stereoisomers were equally effective activators of the purified enzyme (31). These observations would suggest that the signaling pathway involved in the ceramide-mediated induction of IL-6 gene expression may be distinct from that of CAPP activation and the related down-regulation of c-myc (31).

The induction of IL-6 by C2-ceramide appears to be regu-
lated at the transcriptional level, as evidenced by the ability of actinomycin D to completely inhibit ceramide-induced IL-6 production. Further, Northern blot analysis revealed that C2-ceramide induces IL-6 mRNA in a dose-dependent manner with a time course paralleling the accumulation of IL-6 protein. Studies using two different cell types have shown that ceramide activates NF-kB (7, 32), a transcription factor known to be involved in IL-1-induced IL-6 gene expression (33, 34). Therefore, there is a possibility that ceramide may induce IL-6 gene expression through the activation of NF-kB, and experiments designed to test the hypothesis are currently underway.

IL-6 gene regulation has been extensively studied in a wide variety of experimental systems, and the ability of IL-1β to induce IL-6 production is well established. Here we have im-
plicated signaling via the SM pathway in the regulation of
IL-6 gene expression. The induction of IL-6 by ceramide in human fibroblasts demonstrates the ability of a specific SM metabolite to induce the expression of a distinct gene and will provide an excellent model system for studying the mechanisms involved in the regulation of gene expression by SM metabolites.

We are very grateful to Carolyn Chambers for her expert technical assistance.

This work was supported by research funds from the Department of Veterans Affairs and The Arthritis Foundation, and by grants AR39166 and AR26034 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health. R. Raghow is a career scientist of the Department of Veterans Affairs.

Address correspondence to Dr. Leslie R. Ballou, Department of Veterans Affairs Medical Center, Research Service (151), 1030 Jefferson Avenue, Memphis, TN 38104.

Received for publication 17 January 1995 and in revised form 8 March 1995.

References

1. Ballou, L.R. 1992. Sphingolipids and cell function. Immunol. Today. 13:339–341.
2. Hannun, Y.A. 1994. The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem. 269:3125–3128.
3. Kolesnick, R., and D.W. Golde. 1994. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell. 77:325–328.
4. Wiegmann, K., S. Schutze, T. Machleidt, D. Witte, and M. Kronke. 1994. Functional dichotomy of neutral and acidic sphingomyelinasises in tumor necrosis factor signaling. Cell. 78:1005–1015.
5. Dressler, K.A., S. Mathias, and R.N. Kolesnick. 1992. TNF activates the sphingomyelin signal transduction pathway in a cell-free system. Science (Wash. DC). 255:1715–1717.
6. Dbaibo, G.S., L.M. Obeid, and Y.A. Hannun. 1993. Tumor necrosis factor-alpha (TNF-α) signal transduction through ceramide. Dissociation of growth inhibitory effects of TNF-α from activation of nuclear factor-kB. J. Biol. Chem. 268:17762–17766.
7. Schutze, S., K. Pothoff, T. Machleidt, D. Berkovic, K. Wiegmann, and M. Kronke. 1992. TNF activates NF-kB by phosphatidylycholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell. 71:765–776.
8. Kim, M.Y., C. Linardic, L. Obeid, and Y. Hannun. 1991. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor α and γ-interferon. Specific role in cell differentiation. J. Biol. Chem. 266:484–489.
9. Ballou, L.R., C.P. Chao, M.A. Holness, S.C. Barker, and R. Raghow. 1992. Interleukin-1-mediated PGE2 production and sphingomyelin metabolism. Evidence for the regulation of cyclooxygenase gene expression by sphingosine and ceramide. J. Biol. Chem. 267:20044–20050.
10. Mathias, S., C. Younes, C.C. Kan, I. Orlow, C. Joseph, and R.N. Kolesnick. 1993. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1β. Science (Wash. DC). 259:519–522.
11. Okazaki, T., R.M. Bell, and Y.A. Hannun. 1989. Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation. J. Biol. Chem. 264:19076–19080.
12. Linardic, C.M., S. Jayadev, and Y.A. Hannun. 1992. Brefeldin A promotes hydrolysis of sphingomyelin. J. Biol. Chem. 267:14909–14911.
13. Hirano, T. 1992. The biology of interleukin-6. Chem. Immunol. 51:153–180.
14. Hirano, T. 1992. Interleukin-6 and its relation to inflammation and disease. Clin. Immunol. Immunopathol. 62:60–65.
15. Kishimoto, T., S. Akira, and T. Taga. 1992. Interleukin-6 and its receptor: a paradigm for cytokines. Science (Wash. DC). 258:593–597.
16. Kishimoto, T. 1992. Interleukin-6 and its receptor in autoimmunity. J. Autoimmun. 5:123–132.
17. Hirano, T., S. Akira, T. Taga, and T. Kishimoto. 1990. Biological and clinical aspects of interleukin-6. Immunol. Today. 11:443–449.
18. Akira, S., and T. Kishimoto. 1992. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol. Rev. 127:25–50.
19. Lee, F.D. 1992. The role of interleukin-6 in development. Dev. Biol. 151:331–338.
20. Bielawska, A., H.M. Crane, D. Liotta, L.M. Obeid, and Y.A. Hannun. 1993. Selectivity of ceramide-mediated biology. Lack of activity of erythro-dihydroceramide. J. Biol. Chem. 268:26226–26232.
21. Sanmook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. Second edition. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
22. Hirano, T., T. Taga, K. Yasamaki, T. Matsuda, K. Yasuda, Y. Harata, H. Yawata, O. Tanabe, S. Akira, and T. Kishimoto. 1989. Molecular cloning of the cDNAs for interleukin 6/B cell stimulatory factor 2 and its receptor. Ann. NY Acad. Sci. 557:231–238.
23. Ercolani, L., B. Florence, M. Denaro, and M. Alexander. 1988. Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase. J. Biol. Chem. 263:15335–15341.
24. Sehgal, P.B. 1992. Regulation of IL-6 gene expression. Res. Immunol. 143:724–734.
25. Ray, A., S. Laforge, and P.B. Sehgal. 1990. On the mechanism for efficient repression of the IL-6 promoter by glucocorticoids: Enhanced TATA box and RNA start site (INR motif). Mol. Cell. Biol. 10:5736–5746.
26. Sehgal, P.B., Z. Walther, and I. Tamm. 1987. Rapid enhancement of beta 2-interferon/B-cell differentiation factor BSF-2 gene expression in human fibroblasts by diacylglycerols and the calcium ionophore A23187. Proc. Natl. Acad. Sci. USA. 84:3663–3667.
27. Zhang, Y., J.-X. Lin, and J. Vilcek. 1988. Synthesis of interleukin 6 (interferon-beta 2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. J. Biol. Chem. 263:6177–6182.

28. Akira, S., T. Hirano, T. Taga, and T. Kishimoto. 1990. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J. 4:2860–2867.

29. Bielawska, A., C.M. Linardic, and Y.A. Hannun. 1992. Modulation of cell growth and differentiation by ceramide. FEBS Lett. 307:211–214.

30. Obeid, L.M., C.M. Linardic, L.A. Karolak, and Y.A. Hannun. 1993. Programmed cell death induced by ceramide. Science (Wash. DC). 259:1769–1771.

31. Wolff, R.A., R.T. Dobrowsky, A. Bielawska, L.M. Obeid, and Y.A. Hannun. 1994. Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. J. Biol. Chem. 269:19605–19609.

32. Yang, Z., M. Costanzo, D.W. Golde, and R.N. Kolesnick. 1993. Tumor necrosis factor activation of the sphingomyelin pathway signals nuclear factor κB translocation in intact HL-60 cells. J. Biol. Chem. 268:20520–20523.

33. Shimizu, H., K. Mitomo, T. Watanabe, S. Okamoto, and K.-I. Yamamoto. 1990. Involvement of an NF-κB-like transcription factor in the activation of the IL-6 gene by inflammatory cytokines. Mol. Cell. Biol. 10:561–568.

34. Zhang, Y., J.-X. Lin, and J. Vilcek. 1990. IL-6 induction by TNF and IL-1 in human fibroblasts involves activation of a nuclear factor binding to a κB-like sequence. Mol. Cell. Biol. 10:3818–3823.

604 Ceramide Induces IL-6 Gene Expression